ASGCT highlighted a core challenge for AAV gene therapy: redosing constraints driven by pre-existing immunity and immune responses that can limit future administrations. In a roundup of developments, the focus was on how strategies to overcome immunity could restore the ability to treat patients beyond an initial “one-and-done” course, particularly in rare disease settings where long-term disease control may require repeat dosing. The discussion also reflected policy and clinical trial momentum around next-generation capsids and immunomodulatory approaches designed to reduce neutralizing antibody barriers. For developers, the takeaway is operational and clinical—redosing strategies may be essential for broader patient populations and for indications where durability or disease progression demands additional therapy.